Dual-action cancer nanomedicine therapy

Press/Media: Research

Description

A French-Australian research team has fabricated antibody-coated porous silicon nanoparticles that can actively target cells through binding to specific cell-surface receptors. They demonstrated that these nanoparticles can bind to and selectively deliver multiple therapeutics to human B cellsĀ in vitro.

By co-loading a chemotherapy drug with gold nanoclusters, the system took advantage of combined chemotherapy and hyperthermia therapy and provided synergistic effects in eradicating targeted cells.

Period6 Jun 2017

Media contributions

1

Media contributions

  • TitleDual-action cancer nanomedicine therapy
    Media name/outletNano Werk
    Media typeWeb
    Date6/06/17
    DescriptionA French-Australian research team has fabricated antibody-coated porous silicon nanoparticles that can actively target cells through binding to specific cell-surface receptors. They demonstrated that these nanoparticles can bind to and selectively deliver multiple therapeutics to human B cells in vitro.
    By co-loading a chemotherapy drug with gold nanoclusters, the system took advantage of combined chemotherapy and hyperthermia therapy and provided synergistic effects in eradicating targeted cells.
    URLwww.nanowerk.com/nanotechnology_articles/newsid=46956.php
    PersonsAnna Cifuentes Rius, Nicolas Hans Voelcker